Total Payments
$1.9M
2024 Payments
$54,822
Companies
34
Transactions
1,946
Medicare Patients
1,278
Medicare Billing
$3.8M
Payment Breakdown by Category
Other$1.2M (64.3%)
Consulting$337,067 (18.0%)
Travel$212,798 (11.3%)
Research$78,187 (4.2%)
Food & Beverage$39,401 (2.1%)
Education$2,116 (0.1%)
Gifts$33.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 399 | 63.8% |
| Consulting Fee | $337,067 | 77 | 18.0% |
| Travel and Lodging | $212,798 | 355 | 11.3% |
| Unspecified | $78,187 | 153 | 4.2% |
| Food and Beverage | $39,401 | 937 | 2.1% |
| Honoraria | $5,400 | 5 | 0.3% |
| Education | $2,116 | 16 | 0.1% |
| Charitable Contribution | $2,000 | 1 | 0.1% |
| Grant | $2,000 | 1 | 0.1% |
| Gift | $33.00 | 2 | 0.0% |
Payments by Type
General
$1.8M
1,793 transactions
Research
$78,187
153 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $754,924 | 687 | $0 (2024) |
| Genentech USA, Inc. | $497,295 | 385 | $0 (2024) |
| EMD Serono, Inc. | $349,985 | 305 | $0 (2024) |
| Biogen, Inc. | $71,182 | 95 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $50,622 | 154 | $0 (2024) |
| Merck KGaA | $31,579 | 11 | $0 (2023) |
| F. Hoffmann-La Roche AG | $30,931 | 15 | $0 (2020) |
| Medtronic USA, Inc. | $25,960 | 48 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $21,396 | 21 | $0 (2022) |
| TG Therapeutics, Inc. | $8,334 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $54,822 | 101 | EMD Serono, Inc. ($34,676) |
| 2023 | $246,406 | 244 | EMD Serono, Inc. ($165,885) |
| 2022 | $213,961 | 289 | EMD Serono, Inc. ($90,584) |
| 2021 | $161,579 | 222 | Genentech USA, Inc. ($57,656) |
| 2020 | $178,453 | 177 | GENZYME CORPORATION ($80,214) |
| 2019 | $299,688 | 313 | GENZYME CORPORATION ($135,313) |
| 2018 | $322,951 | 259 | GENZYME CORPORATION ($185,746) |
| 2017 | $399,780 | 341 | GENZYME CORPORATION ($254,177) |
All Payment Transactions
1,946 individual payment records from CMS Open Payments — Page 1 of 78
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,537.00 | General |
| 12/03/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,088.00 | General |
| Category: Neurology | ||||||
| 12/03/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $120.19 | General |
| 11/22/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $4.28 | General |
| Category: Neurology | ||||||
| 11/12/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,593.00 | General |
| Category: Neurology | ||||||
| 11/12/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $15.15 | General |
| 10/24/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $20.83 | General |
| 10/23/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $28.22 | General |
| Category: Immunology | ||||||
| 10/22/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $33.89 | General |
| 10/22/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 10/14/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: IMMUNOLOGY | ||||||
| 10/10/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $22.18 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/09/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,560.00 | General |
| 10/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $13.74 | General |
| 09/25/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $6.52 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.41 | General |
| Category: PSYCHIATRY | ||||||
| 09/19/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 09/18/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $11.58 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $8.69 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/17/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $6.73 | General |
| Category: NEUROSCIENCE | ||||||
| 09/16/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $7.99 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/10/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $26.79 | General |
| 09/10/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: NEUROSCIENCE | ||||||
| 09/06/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $17,592 | 19 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $10,547 | 11 |
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $10,521 | 22 |
| An Extension Protocol for Multiple Sclerosis patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $7,835 | 12 |
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) | GENZYME CORPORATION | $6,528 | 22 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of | SANOFI-AVENTIS U.S. LLC | $3,474 | 5 |
| A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) | GENZYME CORPORATION | $3,013 | 14 |
| CAMMS223, CAMMS323 - CARE-MS I, CAMMS324 - CARE-MS II | GENZYME CORPORATION | $2,536 | 7 |
| vsMS Patient Survey | GENZYME CORPORATION | $1,680 | 5 |
| CAMMS324 - CARE-MS II and CAMMS3409 - CARE-MS Extension | GENZYME CORPORATION | $1,526 | 4 |
| Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study Two (CARE-MS II): A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and Hig | GENZYME CORPORATION | $1,481 | 5 |
| MS Patient Survey | GENZYME CORPORATION | $1,269 | 2 |
| A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naive Patients With Relapsing-Remitting Multiple Sclerosis | GENZYME CORPORATION | $1,250 | 1 |
| Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study One (CARE-MS I) : A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment Naive Patients With Relapsing-Remitting Multiple Sclerosis | GENZYME CORPORATION | $1,250 | 1 |
| An Extension Protocol for Multiple Scerlosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,Comparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study One (CARE | GENZYME CORPORATION | $937.55 | 2 |
| An Extension Protocol for Multiple Scerlosis Patients Who Participated in Genzyme-Sponsored Studies of AlemtuzumabComparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study One (CARE | GENZYME CORPORATION | $817.05 | 2 |
| A long-term follow up study for multiple sclerosis patients who have completed the alemtuzumab extension study | GENZYME CORPORATION | $710.74 | 3 |
| Safety and Tolerability of shorter infusion of Ocrevus in MS patients | F. Hoffmann-La Roche AG | $676.31 | 1 |
| Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study Two (CARE-MS II): A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles ,of Intravenous Low- and Hi | GENZYME CORPORATION | $523.60 | 1 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409),An Extension Protocol for Multiple Sclerosis Patients Who Participated in Gen | GENZYME CORPORATION | $446.67 | 1 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409),Comparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study O | GENZYME CORPORATION | $446.67 | 1 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409),Comparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study T | GENZYME CORPORATION | $446.67 | 1 |
| Comparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study One (CARE-MS I) : A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three- | GENZYME CORPORATION | $427.08 | 1 |
| TEMSO (Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis), | SANOFI-AVENTIS U.S. LLC | $397.50 | 1 |
| CAMMS323 - CARE-MS I and CAMMS324 -CARE-MS II | GENZYME CORPORATION | $385.75 | 2 |
| CAMMS223, CAMMS323 - CARE-MS I, and CAMMS324 - CARE-MS II | GENZYME CORPORATION | $366.48 | 1 |
| CAMMS323 - CARE-MS I, CAMMS324 - CARE-MS II, and CAMMS3409 - CARE-MS Extension | GENZYME CORPORATION | $344.93 | 1 |
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study | GENZYME CORPORATION | $319.59 | 2 |
| An Extension Protocol for Multiple Scerlosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose CAMP | GENZYME CORPORATION | $235.62 | 1 |
| Comparison of Alemtuzumab and Rebif Efficacy in Multiple Scerlosis Study Two (CARE-MS II): A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High | GENZYME CORPORATION | $159.98 | 1 |
| CAMMS323 - CARE-MS I and CAMMS3409 - CARE-MS Extension | GENZYME CORPORATION | $43.37 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 276 | 23,045 | $3.7M | $968,751 |
| 2022 | 11 | 390 | 27,372 | $4.4M | $1.2M |
| 2021 | 9 | 338 | 26,687 | $4.4M | $1.1M |
| 2020 | 10 | 274 | 10,766 | $1.8M | $454,247 |
Total Patients
1,278
Total Services
87,870
Medicare Billing
$3.8M
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2023 | 24 | 22,203 | $3.5M | $938,792 | 26.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 61 | 166 | $49,302 | $10,607 | 21.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 44 | 74 | $29,526 | $8,489 | 28.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 28 | 78 | $44,850 | $7,077 | 15.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $6,270 | $1,565 | 25.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 24 | 56 | $7,000 | $1,106 | 15.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 24 | 79 | $5,530 | $845.12 | 15.3% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 23 | 66 | $1,188 | $213.39 | 18.0% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 23 | 41 | $123.00 | $31.52 | 25.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 14 | 271 | $108.40 | $23.79 | 21.9% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2022 | 30 | 26,402 | $4.2M | $1.1M | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 88 | 281 | $83,457 | $19,351 | 23.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 51 | 78 | $31,122 | $9,172 | 29.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 37 | 81 | $47,075 | $7,865 | 16.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 34 | 84 | $10,605 | $1,732 | 16.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $6,270 | $1,630 | 26.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 12 | 28 | $7,420 | $1,382 | 18.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 27 | 53 | $6,625 | $1,157 | 17.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 33 | 86 | $5,952 | $992.41 | 16.7% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2022 | 35 | 207 | $3,780 | $892.08 | 23.6% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2022 | 32 | 61 | $162.60 | $51.56 | 31.7% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2021 | 27 | 25,800 | $4.2M | $1.1M | 26.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 86 | 276 | $81,972 | $23,543 | 28.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 49 | 90 | $35,910 | $11,341 | 31.6% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 33 | 77 | $46,200 | $8,303 | 18.0% |
About Dr. Aaron Boster, MD
Dr. Aaron Boster, MD is a Neurology healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2008. The National Provider Identifier (NPI) number assigned to this provider is 1760641740.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aaron Boster, MD has received a total of $1.9M in payments from pharmaceutical and medical device companies, with $54,822 received in 2024. These payments were reported across 1,946 transactions from 34 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.2M).
As a Medicare-enrolled provider, Boster has provided services to 1,278 Medicare beneficiaries, totaling 87,870 services with total Medicare billing of $3.8M. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Columbus, OH
- Active Since 06/05/2008
- Last Updated 03/13/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1760641740
Products in Payments
- LEMTRADA (Drug) $510,187
- OCREVUS (Biological) $450,780
- Mavenclad (Drug) $157,869
- AUBAGIO (Drug) $152,198
- MAVENCLAD (Drug) $129,917
- Non-Covered Product (Drug) $47,128
- LEMTRADA (Biological) $30,860
- Ocrevus (Biological) $29,599
- GILENYA (Drug) $26,726
- SYNCHROMED (Device) $19,585
- TYSABRI (Biological) $17,101
- KESIMPTA (Drug) $9,654
- TECFIDERA (Drug) $7,802
- ACTHAR (Biological) $7,740
- LIORESAL (Device) $7,440
- NO PRODUCT DISCUSSED (Drug) $7,412
- UPLIZNA (Biological) $7,187
- BRIUMVI (Drug) $6,447
- UPLIZNA (Drug) $6,153
- DISEASE STATE (Drug) $4,071
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Columbus
Kenneth Mankowski, Do, DO
Neurology — Payments: $1.9M
Neurology $1.9M
Danielle Becker, Md, MD
Neurology — Payments: $1.3M
Neurology $1.3M
Dr. Jacqueline Nicholas, M.d, M.D
Neurology — Payments: $967,203
Neurology $967,203
Dr. Jonathan Liss, M.d, M.D
Neurology — Payments: $468,143
Neurology $468,143
Jerry Mendell, Md, MD
Neurology — Payments: $371,804
Neurology $371,804
Dr. Andrew Smith, M.d, M.D
Neurology — Payments: $277,150
Neurology $277,150